A phase I/II clinical trial (NCT02839954) is underway to evaluate the safety and effectiveness of anti‐MUC‐1 CAR‐pNK cells in MUC‐1 positive refractory solid tumours, including liver cancer. Here, MUC1 is linked to liver cancer.